ecNumber*3.4.21.38#specificActivity*-999#specificActivityMaximum*#commentary*limited activation of factor XIIa is sufficient to promote plasma kallikrein activation#organism*Homo sapiens#literature*667868#!ecNumber*3.4.21.38#specificActivity*-999#specificActivityMaximum*#commentary*blood pressure and heart rate response to activated beta-form of human coagulation factor XIIa determined in bioassay rats, eliciting effects on plasma epinephrine and norepinephrine indicated, response to bradykinin tested, kininogen-deficient BNK strains and adrenal medullectomized rats included#organism*Rattus norvegicus#literature*683726#!ecNumber*3.4.21.38#specificActivity*-999#specificActivityMaximum*#commentary*changes of plasma variations of different types of XIIa in relation to thrombolytic therapy by administration of tenecteplase (TNK-tpa), a thrombolytic with a high fibrin specify, blood samples obtained prior to, within, and four days after administration of thrombolytic therapy, ELISA assays measuring different types of XIIa described#organism*Homo sapiens#literature*683828#!ecNumber*3.4.21.38#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*95422#!ecNumber*3.4.21.38#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Bos taurus#literature*95423#